Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice
Abstract Background With expanding therapeutic possibilities for treatment of psoriatic arthritis (PsA) it will be increasingly important to determine residual disease and define when to adjust treatment. The rationale behind treatment decisions in current daily clinical practice and the relationshi...
Main Authors: | Leonieke J. J. van Mens, Marleen G. H. van de Sande, Inka A. Fluri, Sadaf Atiqi, Arno W. R. van Kuijk, Dominique L. P. Baeten |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-017-1424-8 |
Similar Items
-
Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
by: Henriëtte M. Y. de Jong, et al.
Published: (2019-09-01) -
Targeted Therapies in Axial Psoriatic Arthritis
by: Alberto Floris, et al.
Published: (2021-06-01) -
Psoriasis and psoriatic arthritis: Topical issues
by: Yulia Leonidovna Korsakova
Published: (2012-09-01) -
Psoriasis and psoriatic arthritis: Topical issues
by: Yulia Leonidovna Korsakova
Published: (2012-09-01) -
Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis
by: Pedro David Carvalho, et al.
Published: (2017-01-01)